Gramen Botanicals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 07-11-2024
- Paid Up Capital ₹ 1.50 Cr
as on 07-11-2024
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.56 Cr
as on 07-11-2024
- Revenue 36.17%
(FY 2023)
- Profit 43610.06%
(FY 2023)
- Ebitda 461.41%
(FY 2023)
- Net Worth 451.35%
(FY 2023)
- Total Assets -20.37%
(FY 2023)
About Gramen Botanicals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹4.56 Cr.
Samarth Singh and Neelam Singh serve as directors at the Company.
- CIN/LLPIN
U85100UR2020PTC010675
- Company No.
010675
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jan 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Nainital, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Gramen Botanicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Samarth Singh  | Director | 20-Jan-2020 | Current |
| Neelam Singh | Director | 15-Nov-2020 | Current |
Financial Performance of Gramen Botanicals.
Gramen Botanicals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 36.17% increase. The company also saw a substantial improvement in profitability, with a 43610.06% increase in profit. The company's net worth Soared by an impressive increase of 451.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gramen Botanicals?
Unlock access to Gramen Botanicals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Folius Laboratories Private LimitedActive 3 years 6 months
Samarth Singh and Neelam Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Feb 2024 | ₹3.06 M | Open |
Others Creation Date: 14 Jul 2020 | ₹4.25 Cr | Open |
How Many Employees Work at Gramen Botanicals?
Gramen Botanicals has a workforce of 36 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gramen Botanicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gramen Botanicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
